Holen Sie sich die Stockscreener-App
14.38
3.79%
0.51
Handel nachbörslich:
14.45
0.07
+0.49%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$13.87
Offen:
$13.69
24-Stunden-Volumen:
3.10M
Relative Volume:
1.49
Marktkapitalisierung:
$971.65M
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-6.8804
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
-0.86%
1M Leistung:
+17.32%
6M Leistung:
-15.47%
1J Leistung:
-61.47%
1-Tages-Spanne:
$13.50
$14.46
1-Wochen-Bereich:
$13.49
$15.57
52-Wochen-Spanne:
$9.98
$38.28
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
14.38 | 937.19M | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
133.26 | 228.66B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
96.24 | 140.69B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.88 | 139.51B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.53 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.35 | 42.83B | 5.69B | 1.41B | 577.90M | 6.9828 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Can Tandem Diabetes Care Inc. stock hit analyst price targetsEarnings Overview Summary & Weekly Top Stock Performers List - newser.com
Real time pattern detection on Tandem Diabetes Care Inc. stockWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc.TNDM - PR Newswire
Candlestick signals on Tandem Diabetes Care Inc. stock todayWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
Using R and stats models for Tandem Diabetes Care Inc. forecasting2025 Volatility Report & Growth Focused Entry Point Reports - newser.com
Tandem Diabetes Care Inc. stock momentum explainedDividend Hike & High Accuracy Investment Signals - newser.com
Is Tandem Diabetes Care Inc. stock a buy on dips2025 Valuation Update & Trade Opportunity Analysis Reports - newser.com
Is this a good reentry point in Tandem Diabetes Care Inc.Earnings Miss & Daily Profit Focused Stock Screening - newser.com
What indicators show strength in Tandem Diabetes Care Inc.Weekly Trend Summary & Comprehensive Market Scan Insights - newser.com
Combining machine learning predictions for Tandem Diabetes Care Inc.2025 Volatility Report & Expert Curated Trade Setups - newser.com
Weekly Investment Analysts’ Ratings Updates for Tandem Diabetes Care (TNDM) - Defense World
Will Tandem Diabetes Care Inc. (TD5A) stock keep raising dividendsJuly 2025 Recap & Safe Investment Capital Preservation Plans - newser.com
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - Eastern Progress
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know - TradingView
United States Wearable Injectors Market 2025 | Industry - openPR.com
Can Tandem Diabetes Care Inc. stock deliver sustainable ROEJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
Is Tandem Diabetes Care Inc. stock attractive after correction2025 Price Action Summary & Reliable Entry Point Trade Alerts - newser.com
Lobbying Update: $50,000 of TANDEM DIABETES CARE lobbying was just disclosed - Quiver Quantitative
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Is Tandem Diabetes Care Inc. (TD5A) stock undervalued after correctionTrade Risk Summary & Community Trade Idea Sharing - newser.com
Should you hold or exit Tandem Diabetes Care Inc. nowJuly 2025 Short Interest & Breakout Confirmation Trade Signals - newser.com
Could Tandem Diabetes Care’s (TNDM) Risk Profile Shift After Device Malfunction and New FDA Clearance? - Sahm
Ongoing Securities Investigation into Tandem Diabetes Care, Inc. (TNDM)Contact Levi & Korsinsky - Newsfile
Tandem Diabetes Care Stock Soars 12.2% to Intraday High of $14.85 - Markets Mojo
Tandem Diabetes Care Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
INVESTOR ALERT: Investigation of Tandem Diabetes Care, Inc. (TNDM) Announced by Holzer & Holzer, LLC - GlobeNewswire
TNDM: Citigroup Raises Price Target to $15, Maintains Neutral Ra - GuruFocus
Tandem Diabetes Care (TNDM): Assessing Valuation After Lyumjev Compatibility Expands Insulin Pump Options - Sahm
Shareholders Alert: Investigation Into Tandem Diabetes Care, Inc. (TNDM)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Why Analysts Are Reassessing Tandem Diabetes Care as Its Growth Story Evolves - Yahoo Finance
Is Tandem Diabetes Care Inc. (TD5A) stock a contrarian opportunityPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Is Tandem Diabetes Care Inc. (TD5A) stock a top pick for value investorsJuly 2025 EndofMonth & High Accuracy Swing Entry Alerts - newser.com
Fraud Investigation Opened: Levi & Korsinsky Investigates Tandem Diabetes Care, Inc. (TNDM) on Behalf of Shareholders - ACCESS Newswire
Published on: 2025-10-06 08:09:28 - earlytimes.in
Investors in Tandem Diabetes Care, Inc. (TNDM) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Forecasting Tandem Diabetes Care Inc. price range with options dataEarnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
Published on: 2025-10-05 04:46:17 - newser.com
Applying big data sentiment scoring on Tandem Diabetes Care Inc.Quarterly Market Review & Fast Gain Stock Trading Tips - newser.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc.TNDM - MarketScreener
Does Tandem Diabetes Care Inc. fit your quant trading modelJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.22%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):